Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10269902 | PMC |
| http://dx.doi.org/10.3389/fpsyg.2023.1184939 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Citizen of science.
Science
January 2025
H. Holden Thorp is Editor-in-Chief of the Science journals.
Floyd Bloom, who died on 8 January, was a towering figure in both neuroscience and the scientific community as a whole. As Editor-in-Chief of from 1995 to 2000, he presided over a transformative period in which the journal embraced the digital age, expanding its reach and impact while advocating for open access and the sharing of data. His groundbreaking contributions to neuropharmacology and the understanding of neurotransmitters were only part of his legacy.
View Article and Find Full Text PDFAdvancing Global Health Equity: Saudi Arabia's Leadership in Conjoined Twins Care and Humanitarian Outreach.
J Epidemiol Glob Health
January 2025
College of Medicine, King Salman Humanitarian Aid & Relief Center, Alfaisal University, Kingdom of Saudi Arabia & Abu Dhabi University, Riyadh, UAE.
The Genesis of the Academy of Diversity Leaders in Nursing.
Am J Nurs
February 2025
Kenya Beard is dean and chief nursing officer at the Mercy University School of Nursing, Dobbs Ferry, NY, and a member of AJN's editorial board. Sheldon Fields is associate dean at Penn State University, University Park, PA. Contact author: Kenya Beard, The authors have disclosed no potential conflicts of interest, financial or otherwise.
Combating all forms of oppression to achieve health equity.
View Article and Find Full Text PDFPeritoneal dialysis in patients with severe obesity: A successful single center experience.
Perit Dial Int
January 2025
Division of Nephrology, Department of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.
There is growing emphasis on increasing utilization of peritoneal dialysis (PD) in patients with end stage kidney disease (ESKD); however, use in patients with severe obesity has still been fraught for various reasons. We aim to assess the viability of PD in patients with severe obesity (BMI > 40 Kg/m). We conducted a retrospective chart review of patients admitted at the home dialysis center of an academic center between 2014 and 2020 (n = 99).
View Article and Find Full Text PDFInitial clinical experience with [Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial.
Front Oncol
January 2025
Department of Clinical Development, POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company, Indianapolis, IN, United States.
Introduction: SPLASH (NCT04647526) is a multicenter phase III trial evaluating the efficacy and safety of [Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC). This study leveraged a lead-in phase to assess tissue dosimetry and evaluate preliminary safety and efficacy, prior to expansion into a randomized phase. Here we report those results.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!